• Skip to main content
  • Skip to footer
  • UCI
  • Office of the Provost
  • Academic Initiatives
Donate
Follow IDSI on Twitter!
id science logo
  • Research
  • Publications
  • About Us
    • Leadership & Staff
    • Faculty Advisory Board
    • Affiliate Faculty
    • Contact Us
  • News
  • Events
  • Education & Training
  • Funding Opportunities
  • Resources
    • Coronavirus Disease (COVID-19) Outbreak Resources

IDSI Affiliates Faculty Dr. Bernadette Boden-Albala ft BeckersHR “FDA panel votes for bivalent COVID-19 shots, debates ‘annual’ schedule”.

You are here: Home / News & Announcements / IDSI Affiliates Faculty Dr. Bernadette Boden-Albala ft BeckersHR “FDA panel votes for bivalent COVID-19 shots, debates ‘annual’ schedule”.

January 27, 2023

Meeting based on all COVID-19 vaccines and how it should be targeted to the original and dominant strains, an FDA advisory panel said Jan. 26, but members debated whether a new modified vaccine every 12 months is optimal.

After a daylong meeting discussing tentative changes to the nation's COVID-19 vaccine strategy, the FDA's Vaccines and Related Biological Products Advisory Committee voted 21-0 recommending the primary series also include the modified, bivalent vaccines.

Three more takeaways from the meeting:

1. The panel discussed — but did not vote on — whether to model the COVID-19 vaccine regimen to copy an annual schedule similar to flu shots. Most argued against this approach because COVID-19 does not mutate on a yearly basis, meaning another tweaked vaccine may be necessary in the summer or every 18 months.

2. One adviser questioned whether focusing solely on the bivalent model would compromise broad protection, but most showed interest in continuously updating the vaccine's composition. "It may be bigger bang for our buck," one panel member said.

3. The committee also debated simplifying the immunization schedule to direct two doses for children and immunocompromised people and one dose for the rest of the public. The consensus was there is not enough information about T-cell, B-cell, non-neutralizing antibody responses or data about protein-based and mucosal-based shots.

Read More

News & Announcements,  Research

Footer

Coronavirus Disease (COVID-19) Outbreak Resources

COVID-19

Resources

medical technology

Research

map of the world

Publications

magnifying glass
Get In Touch!

Office of Academic Planning
535 Aldrich Hall
University of California, Irvine
Irvine, CA 92697-1000

idinitiative@uci.edu

 

 

About Us

UCI Infectious Disease Science Initiative aims to position UCI as a global leader in research and education in infectious disease dynamics by fueling the development of new knowledge and insights into the dynamics of infectious diseases and drug resistance.

© 2019 UC Regents  |  Privacy Policy